CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

CHEPLAPHARM acquires rights to Rivotril®

Greifswald, 01/11/2021 - CHEPLAPHARM expanded its portfolio by acquiring the commercial rights for Rivotril® from Roche.

"As a successful start to the new year, we were able to complete this very important project for CHEPLAPHARM, which perfectly complements our portfolio of globally marketed benzodiazepines. We are proud to build on a long-standing relationship with Roche," says CEO Sebastian F. Braun, “and are pleased with the acquisition of the established brand among patients and prescribers.”

Rivotril® is a branded prescription drug which is commonly used and indicated in the therapeutic area of eplilepsy and panic disorder. This benzodiazepine with the active ingredient clonazepam is a well-established, globally marketed product. Rivotril® was launched in 1973 and is currently registered in approximately 85 countries.

Investor Relations topics

Back to top expand_less